Payment overview · 2025
General Payments
$870.96
44 reported records · 14 companies
Healthcare provider profile · identity verified
Roger Carr, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FAYETTEVILLE, GA · NPI 1215011663
Verified facts
What the public records show
CMS Open Payments records show Roger Carr, M.D. received $870.96 in general payments during 2025 across 44 reported records.
Novo Nordisk Inc accounted for 25.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 236 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 272 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $219.73 | 25.2% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $205.07 | 23.6% | 12 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $86.26 | 9.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $67.05 | 7.7% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $66.24 | 7.6% | 4 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $64.84 | 7.4% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$37.23 | 4.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.51 | 2.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.14 | 2.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.76 | 2.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.73 | 1.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.57 | 1.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.54 | 1.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.29 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $870.96 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $162.86 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $162.86 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $101.34 | 6 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $86.26 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $81.56 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $67.05 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $67.05 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $66.24 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $66.24 | 4 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $64.84 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $56.87 | 3 | 2025 |
Source payment records
|
|||||
| INTERSTIM Normalized: interstim |
Device | Medtronic, Inc. | $37.23 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.51 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.14 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.85 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 236 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 177 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 58 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 87 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 272 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 74 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
58 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
66 | 23 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
236 | 53 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
177 | 52 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
74 | 56 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
122 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
177 | 52 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
87 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
79 | 19 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
272 | 50 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1236 | 402 |
| Amlodipine Besylate | Amlodipine Besylate | 1214 | 401 |
| Pravastatin Sodium | Pravastatin Sodium | 664 | 190 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 658 | 230 |
| Pantoprazole Sodium | Pantoprazole Sodium | 582 | 210 |
| Gabapentin | Gabapentin | 561 | 181 |
| Levothyroxine Sodium | Levothyroxine Sodium | 529 | 163 |
| Losartan Potassium | Losartan Potassium | 509 | 160 |
| Famotidine | Famotidine | 495 | 178 |
| Tramadol Hcl | Tramadol Hcl | 429 | 117 |
| Metformin Hcl | Metformin Hcl | 427 | 137 |
| Diclofenac Sodium | Diclofenac Sodium | 408 | 195 |
| Metoprolol Succinate | Metoprolol Succinate | 407 | 138 |
| Hydrochlorothiazide | Hydrochlorothiazide | 405 | 133 |
| Lisinopril | Lisinopril | 388 | 130 |
| Furosemide | Furosemide | 363 | 131 |
| Carvedilol | Carvedilol | 326 | 108 |
| Tamsulosin Hcl | Tamsulosin Hcl | 288 | 94 |
| Omeprazole | Omeprazole | 283 | 98 |
| Glimepiride | Glimepiride | 273 | 78 |
| Ozempic | Semaglutide | 272 | 50 |
| Simvastatin | Simvastatin | 254 | 77 |
| Fluticasone Propionate | Fluticasone Propionate | 251 | 102 |
| Farxiga | Dapagliflozin Propanediol | 236 | 53 |
| Alendronate Sodium | Alendronate Sodium | 222 | 65 |
| Potassium Chloride | Potassium Chloride | 220 | 89 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 213 | 101 |
| Metoprolol Tartrate | Metoprolol Tartrate | 204 | 73 |
| Valsartan | Valsartan | 202 | 61 |
| Allopurinol | Allopurinol | 197 | 61 |
| Meloxicam | Meloxicam | 197 | 72 |
| Alprazolam | Alprazolam | 195 | 62 |
| Nifedipine Er | Nifedipine | 194 | 63 |
| Metformin Hcl Er | Metformin Hcl | 187 | 54 |
| Eliquis | Apixaban | 183 | 63 |
| Jardiance | Empagliflozin | 177 | 52 |
| Ezetimibe | Ezetimibe | 176 | 63 |
| Tizanidine Hcl | Tizanidine Hcl | 176 | 65 |
| Atenolol | Atenolol | 174 | 54 |
| Mirtazapine | Mirtazapine | 174 | 68 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 169 | 56 |
| Montelukast Sodium | Montelukast Sodium | 159 | 54 |
| Donepezil Hcl | Donepezil Hcl | 158 | 48 |
| Prednisone | Prednisone | 155 | 125 |
| Trazodone Hcl | Trazodone Hcl | 154 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 145 | 55 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 145 | 53 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 138 | 77 |
| Duloxetine Hcl | Duloxetine Hcl | 137 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 125 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 124 | 43 |
| Clonidine Hcl | Clonidine Hcl | 122 | 41 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 122 | 31 |
| Meclizine Hcl | Meclizine Hcl | 114 | 65 |
| Ibuprofen | Ibuprofen | 107 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 106 | 33 |
| Lorazepam | Lorazepam | 102 | 27 |
| Finasteride | Finasteride | 99 | 33 |
| Spironolactone | Spironolactone | 98 | 36 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 93 | 30 |
| Methocarbamol | Methocarbamol | 92 | 36 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 91 | 30 |
| Mounjaro | Tirzepatide | 87 | 23 |
| Sertraline Hcl | Sertraline Hcl | 85 | 35 |
| Buspirone Hcl | Buspirone Hcl | 84 | 32 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 79 | 73 |
| Trulicity | Dulaglutide | 79 | 19 |
| Baclofen | Baclofen | 75 | 49 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 74 | 56 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 26 |
| Colchicine | Colchicine | 72 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 16 |
| Memantine Hcl | Memantine Hcl | 70 | 21 |
| Propranolol Hcl | Propranolol Hcl | 70 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 70 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 68 | 24 |
| Celecoxib | Celecoxib | 67 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 67 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 20 |
| Naproxen | Naproxen | 66 | 33 |
| Solifenacin Succinate | Solifenacin Succinate | 66 | 22 |
| Synthroid | Levothyroxine Sodium | 66 | 23 |
| Warfarin Sodium | Warfarin Sodium | 66 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 62 | 62 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 59 | 23 |
| Januvia | Sitagliptin Phosphate | 59 | 19 |
| Linzess | Linaclotide | 58 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 57 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 24 |
| Ondansetron Odt | Ondansetron | 56 | 32 |
| Pregabalin | Pregabalin | 56 | 22 |
| Valacyclovir | Valacyclovir Hcl | 56 | 27 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 55 | 17 |
| Benazepril Hcl | Benazepril Hcl | 55 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 54 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 49 | 15 |
| Repatha Sureclick | Evolocumab | 48 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 48 | 23 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 46 | 27 |
| Xarelto | Rivaroxaban | 46 | 12 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 44 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 43 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 17 |
| Glipizide | Glipizide | 43 | 16 |
| Irbesartan | Irbesartan | 43 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 43 | suppressed |
| Azithromycin | Azithromycin | 40 | 38 |
| Ketoconazole | Ketoconazole | 40 | 26 |
| Clonazepam | Clonazepam | 39 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 37 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 37 | 14 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 36 | 35 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 35 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 32 |
| Bupropion Xl | Bupropion Hcl | 34 | 14 |
| Clonidine | Clonidine | 34 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 34 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 34 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 33 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | suppressed |
| Lovastatin | Lovastatin | 32 | 11 |
| Belsomra | Suvorexant | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Levemir Flexpen | Insulin Detemir | 31 | 11 |
| Sucralfate | Sucralfate | 31 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | 12 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 30 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 29 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 29 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 29 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 15 |
| Fluconazole | Fluconazole | 27 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Mupirocin | Mupirocin | 26 | 21 |
| Telmisartan | Telmisartan | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Cilostazol | Cilostazol | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Ibu | Ibuprofen | 25 | 12 |
| Novolog Flexpen | Insulin Aspart | 25 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | 11 |
| Estradiol | Estradiol | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 22 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 22 | 13 |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Klor-Con M10 | Potassium Chloride | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Verapamil Sr | Verapamil Hcl | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Pentoxifylline | Pentoxifylline | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Cefaclor | Cefaclor | 14 | 12 |
| Digoxin | Digoxin | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Cabergoline | Cabergoline | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | 12 |
| Diazepam | Diazepam | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Tdvax | Tetanus, Diphtheria Tox,adult | 12 | 12 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $870.96 · 44 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, BREZTRI, FARXIGA, FREESTYLE LIBRE 3, INTERSTIM, JARDIANCE, LEQVIO, LINZESS, MOUNJARO, OTEZLA, Omnipod, Ozempic, REPATHA, Rybelsus, SHINGRIX, TZIELD, The Cologuard Plus Collection Kit, Veozah, Wegovy, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error